BMJ22h
Gut microbiome in rheumatic diseases
Correspondence to Professor Sergey Moiseev, Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow 119435, Russian Federation; avt420034{at}yahoo.com Gut microbiome ...
BMJ22h
A disease activity score for polymyalgia rheumatica
Objective: To develop a composite score for measurement of disease activity in polymyalgia rheumatica (PMR) and assess its internal and external validity. Methods: A PMR activity score (AS) was ...
BMJ3d
Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial
Dr C H M van den Ende, Leiden University Medical Centre, Department of Rheumatology, C4-R, Postbox 9600, 2300 RC Leiden, The Netherlands Email:e.vandenende{at}nivel.nl OBJECTIVE To investigate the ...
BMJ3d
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study
1 Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria 2 Second Department of Medicine, Lainz Hospital, Vienna, Austria Correspondence to: Dr D Aletaha, ...
BMJ3d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ3d
Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
Correspondence to Dr Peter Kvacskay, Department of Internal Medicine V Hematology Oncology Rheumatology, University Hospital Heidelberg, Heidelberg 69120, Germany; peter.kvacskay{at}med.uni-heidelberg ...
BMJ4d
FRI0558 Rheumatoid Arthritis Prevalence in Europe, A Eular-Endorsed Survey
Background Various rheumatoid arthritis (RA) prevalence estimates have been reported across Europe, but differences in methodology made it difficult to disentangle true heterogeneity (1). A unique RA ...
BMJ4d
Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis
Correspondence to Professor Daniel Aletaha, Department of Medicine III, Medical University of Vienna, Wien 1090, Austria; daniel.aletaha{at}meduniwien.ac.at Objectives To investigate whether treatment ...
BMJ5d
Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology
2 Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK 3 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK 4 Institute of ...
BMJ6d
Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis
1 Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy 2 Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy 3 Università degli ...
BMJ6d
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study
11 Paris-Descartes University, Medicine Faculty, UPRES-EA 4058 & APHP, Cochin Hospital, Rheumatology B Department, Paris, France Correspondence to Professor Maxime Dougados, Paris-Descartes University ...
BMJ6d
Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis
Objective We aimed to understand the role of the transcriptional co-factor Yes-associated protein (Yap) in the molecular pathway underpinning the pathogenic transformation of synovial fibroblasts (SF) ...